Abstract
NICE evaluates all new active substances; since 2016 the Cancer Drugs Fund (CDF) has supported earlier access to promising cancer treatments, whilst further data is collected to address evidential uncertainties. The Innovative Medicines Fund (IMF) extended this managed access (MA) approach to any condition. We present a comparative analysis of recommendations by rarity of disease to provide insight about rare diseases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
